XORTX Therapeutics Files September 2025 6-K Report
Ticker: XRTX · Form: 6-K · Filed: Sep 4, 2025 · CIK: 1729214
Sentiment: neutral
Topics: reporting, compliance, foreign-private-issuer
TL;DR
XORTX filed its monthly 6-K, confirming 20-F annual reports and signed by CEO Davidoff.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on September 4, 2025, to report for the month of September 2025. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. The report was signed by CEO Allen Davidoff.
Why It Matters
This filing serves as an update for investors regarding the company's reporting status and compliance with SEC regulations for foreign private issuers.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- September 4, 2025 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
Which annual report form does XORTX Therapeutics Inc. file?
XORTX Therapeutics Inc. files its annual reports under cover of Form 20-F.
Who signed the Form 6-K filing on behalf of XORTX Therapeutics Inc.?
The Form 6-K filing was signed by Allen Davidoff, Chief Executive Officer.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is September 4, 2025.
What is the SIC code for XORTX Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for XORTX Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2025-09-04 07:36:09
Filing Documents
- f6k_090425.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-25-005726.txt ( ) — 12KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: September 4, 2025 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated September 4, 2025